about
CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysisLocalised extranodal lymphoma of the head and neck: the Sheffield Lymphoma Group experience (1971-2000).Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trialSecond primary malignancies after treatment for malignant lymphoma.Primary thyroid lymphoma: the 40 year experience of a UK lymphoma treatment centre.An orientation anisotropy in the effects of scaling vertical disparities.The relationship between smoking and quality of life in advanced lung cancer patients: a prospective longitudinal study.Health care workers and HIV/AIDS: a critical review of the literature.Poor outcome in adolescents with high-risk Hodgkin lymphoma.Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients.Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.Quality of life, support and smoking in advanced lung cancer patients: a qualitative study.Peripheral T cell lymphoma: The Sheffield Lymphoma Group experience (1977-2001)Localised extranodal non-Hodgkin's lymphoma of the gastrointestinal tract: Sheffield Lymphoma Group experience (1989-1998)Non-Hodgkin's lymphoma presenting with spinal involvement: the Sheffield Lymphoma Group experience (1970-2000)Is there a relationship between treatment for infertility and gestational trophoblastic disease?T-cell non-Hodgkin's lymphoma: treatment outcomes and survival in 3 large UK centresPrimary bone lymphoma: a retrospective analysisImpact of the revised FIGO/WHO system on the management of patients with gestational trophoblastic neoplasiaAn exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone painIntensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours
P50
Q26999715-F24822FC-D822-4E0D-BA1D-795D097341DDQ35801319-23B21DF8-021F-4B77-9CC2-3BA8E7950EDEQ36491348-43751CC1-C266-464D-8EA1-4DC6671B74F9Q36615187-B40E34CC-3B81-4588-AA5A-7D059CA42848Q37988357-D5BDC4AE-411A-4C95-BCBA-9466A1657717Q39438862-A6BA71BC-3E4C-4FF1-9D81-850DAEF47981Q40545360-9BF11ED9-6414-47AF-A9E4-BA4F589F5044Q40964560-E68E5A50-67FB-4668-A10F-7CEEE20B479CQ43796612-B719C98F-74CE-48EE-9220-43379EC6F9E5Q44287668-0C3411D3-35E8-4960-B6EE-4CCD3A75EFB0Q46336448-0938A1F8-D817-4B98-912D-A30D1E246D99Q48077813-7806D00C-9277-4491-9C0C-ADAC1E22AE45Q73373258-42841B13-0AF8-4D7C-A071-6168434BE3C6Q73620720-CB1A3035-8F02-4E50-9B0E-3621CD305310Q74027852-AA34F774-DF20-4A1B-97B7-98BA63B9A887Q75345924-7B47C67B-AEBC-4BFD-9504-18E7A2595EF0Q81039990-6A2E60ED-BA9A-4BFB-9C18-57EB6657F1D7Q83311844-6C6B72BE-3E2B-446B-BB67-C3466B78EA1DQ83446128-9E283245-38BC-4A9D-9984-883D06B13978Q91015640-0BB12CC6-01B5-4E28-9242-00EFDDCBF51AQ91816274-A96EBA72-CDCC-4ABC-A45E-BE7A4DF52B42
P50
description
researcher
@en
wetenschapper
@nl
name
J M Horsman
@en
J M Horsman
@nl
type
label
J M Horsman
@en
J M Horsman
@nl
prefLabel
J M Horsman
@en
J M Horsman
@nl
P106
P31
P496
0000-0002-6454-642X